$599
Merck’s Oral PCSK9i Approved by FDA; BI Ph2 Triple Agonist Study; Abbott Q2 ’26 Earnings; Syntis Ph1 Obesity Data; Lilly Invests in Oura; Braveheart IPO
A series of cardiometabolic-related news items has been observed from Merck, Boehringer Ingelheim, Abbott, Syntis Bio, Oura/Lilly, and Braveheart. Below, FENIX provides highlights and insights for the respective news items.
This content is for Read Less members only.
Already a member? Log in here
OR